Should the Use of the Extended Myositis Antibody (EMA) Panel Be Part of the Routine Work-Up in Suspected Myositis? (P5.038)

Conclusions: This study illustrates the value of the EMA panel in defining a heterogeneous patient population into clinicoserological phenotypes, and consequently guiding investigation and treatment pathways. Furthermore, it highlights the diversity of possible presentation with subsequent need for multi-speciality involvement, and serves to heighten awareness among clinicians of the diagnostic use of extended myositis antibody testing in these cases. Referneces: 1. Hengstman GJD, Van Engelen BGM, Vree Egberts WTM, et al. Myositis specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001 Nov;13:476-8.Disclosure: Dr. O' Connor has nothing to disclose. Dr. Mulhall has nothing to disclose. Dr. Harney has nothing to disclose. Dr. Ryan has nothing to disclose. Dr. Murphy has nothing to disclose. Dr. Henry has nothing to disclose. Dr. Annis has nothing to disclose. Dr. Ryan has received personal compensation for activities with Novartis, Merck Serono and Teva pharmaceuticals as a speaker and consultant.
Source: Neurology - Category: Neurology Authors: Tags: Pathomechanism and Biomarkers in Muscle Diseases and Myasthenia Source Type: research